Coherus Content With Dual Pipeline Strategy
US Firm Reveals Full-Year Udenyca Biosimilar Sales
Coherus BioSciences sees value in having both wholly-owned and in-licensed biosimilar assets, as the firm gears up to have a portfolio of at least six products within five years.
